Share Price and Basic Stock Data
Last Updated: December 29, 2025, 10:39 am
| PEG Ratio | 5.23 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Fortis Healthcare Ltd operates within the Hospitals & Medical Services sector, demonstrating a robust growth trajectory in its revenue. For the financial year ending March 2025, the company reported total sales of ₹7,783 Cr, reflecting a significant increase from ₹6,298 Cr in March 2023. This upward trajectory is further highlighted by quarterly sales figures, where revenue rose from ₹1,488 Cr in June 2022 to ₹1,657 Cr in June 2023, and continued to grow to ₹1,770 Cr by September 2023. Fortis has consistently improved its sales performance, with a trailing twelve months (TTM) revenue standing at ₹8,434 Cr. The company’s operating profit margin (OPM) is reported at 20%, indicating a healthy operational efficiency relative to the industry. The ability to maintain a steady revenue increase amidst a dynamic healthcare environment positions Fortis as a competitive player in the sector, with strategic initiatives likely contributing to this growth.
Profitability and Efficiency Metrics
Fortis Healthcare’s profitability metrics exhibit a solid performance, with a net profit of ₹1,038 Cr reported for the financial year ending March 2025. This marks a substantial increase from ₹633 Cr in March 2023, showcasing the company’s effective cost management and operational efficiency. The operating profit margin (OPM) has also improved, rising to 20% from 17% in March 2023. Efficiency ratios, such as the interest coverage ratio (ICR), stand at 8.97x, indicating strong earnings relative to interest obligations, which enhances financial stability. Additionally, the return on equity (ROE) is reported at 10.1%, while the return on capital employed (ROCE) is 12%, reflecting the company’s ability to generate returns on shareholder and capital investments effectively. Overall, these metrics underline Fortis Healthcare’s capacity to sustain profitability while managing operational costs effectively.
Balance Sheet Strength and Financial Ratios
Fortis Healthcare’s balance sheet reflects a stable financial position, with total assets reported at ₹13,377 Cr as of March 2025. The company’s reserves have increased to ₹8,674 Cr, indicating a strong buffer for future investments and operations. Borrowings, however, stood at ₹3,195 Cr, which may raise concerns regarding leverage; however, the low total debt to equity ratio of 0.24x suggests that the company is not overly reliant on debt financing. The current ratio is reported at 0.91x, slightly below the industry standard, which may indicate potential liquidity challenges. Fortis’s price-to-book value (P/BV) ratio of 5.91x is notably high, reflecting market confidence but also suggesting that the stock may be overvalued relative to its book value. Collectively, these financial ratios depict a company with a solid capital structure, though careful monitoring of debt levels and liquidity will be essential moving forward.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Fortis Healthcare reveals a balanced distribution among various investor categories. Promoters hold 31.17% of the company, indicating a stable control structure. Foreign Institutional Investors (FIIs) have a significant stake of 27.90%, while Domestic Institutional Investors (DIIs) hold 29.14%. This diversified ownership structure suggests healthy investor confidence. However, the public shareholding has decreased to 11.79%, which may indicate a preference among institutional investors for Fortis’s stock. The total number of shareholders has increased to 2,20,766, reflecting growing interest and potential retail investor engagement. The dividend payout ratio for the financial year ending March 2025 is reported at 9.99%, which, although modest, signals a commitment to returning value to shareholders. Overall, the shareholding dynamics and increasing shareholder base reflect a positive outlook for investor engagement and confidence in Fortis’s strategic direction.
Outlook, Risks, and Final Insight
Looking ahead, Fortis Healthcare is well-positioned to capitalize on the increasing demand for healthcare services, driven by an expanding middle class and heightened health awareness among consumers. However, risks include potential regulatory changes and the challenge of maintaining operational efficiency amid rising costs. The healthcare sector’s inherent volatility and competition may also pose challenges to sustaining growth rates. In terms of strengths, Fortis benefits from a solid financial foundation, strong profitability metrics, and a diversified investor base, which collectively enhance its resilience. The company’s ability to adapt to market dynamics and innovate within its service offerings will be crucial for future growth. Overall, Fortis Healthcare’s current trajectory suggests a promising outlook, provided it effectively navigates potential risks in the evolving healthcare landscape.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| NG Industries Ltd | 44.8 Cr. | 134 | 187/120 | 9.14 | 117 | 2.62 % | 23.6 % | 20.7 % | 10.0 |
| Global Longlife Hospital and Research Ltd | 24.5 Cr. | 23.4 | 35.5/15.5 | 24.3 | 0.00 % | 13.7 % | 17.7 % | 10.0 | |
| Gian Lifecare Ltd | 7.90 Cr. | 7.64 | 20.8/7.08 | 87.8 | 19.1 | 0.00 % | 3.00 % | 0.81 % | 10.0 |
| Fortis Malar Hospitals Ltd | 112 Cr. | 59.9 | 98.7/55.2 | 24.8 | 18.3 | 0.00 % | 0.83 % | 0.56 % | 10.0 |
| Family Care Hospitals Ltd | 19.8 Cr. | 3.67 | 7.29/3.40 | 1.51 | 0.00 % | 79.2 % | 85.5 % | 10.0 | |
| Industry Average | 26,241.93 Cr | 692.99 | 92.44 | 93.18 | 0.33% | 15.48% | 14.81% | 9.04 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,488 | 1,607 | 1,560 | 1,643 | 1,657 | 1,770 | 1,680 | 1,786 | 1,859 | 1,988 | 1,928 | 2,007 | 2,167 |
| Expenses | 1,237 | 1,304 | 1,283 | 1,372 | 1,386 | 1,440 | 1,396 | 1,405 | 1,516 | 1,554 | 1,553 | 1,572 | 1,676 |
| Operating Profit | 251 | 303 | 276 | 271 | 272 | 330 | 284 | 381 | 343 | 435 | 375 | 435 | 491 |
| OPM % | 17% | 19% | 18% | 16% | 16% | 19% | 17% | 21% | 18% | 22% | 19% | 22% | 23% |
| Other Income | 31 | 75 | 26 | 26 | 10 | 18 | 19 | 17 | 14 | -42 | 47 | -29 | 31 |
| Interest | 31 | 33 | 33 | 32 | 31 | 32 | 33 | 35 | 35 | 36 | 45 | 68 | 70 |
| Depreciation | 74 | 77 | 83 | 82 | 79 | 84 | 87 | 92 | 91 | 95 | 97 | 102 | 101 |
| Profit before tax | 176 | 268 | 186 | 183 | 171 | 233 | 183 | 271 | 230 | 261 | 279 | 237 | 351 |
| Tax % | 24% | 19% | 24% | 25% | 27% | 21% | 27% | 25% | 24% | 26% | 9% | 21% | 24% |
| Net Profit | 134 | 218 | 142 | 138 | 124 | 184 | 134 | 203 | 174 | 193 | 254 | 188 | 267 |
| EPS in Rs | 1.62 | 2.71 | 1.72 | 1.76 | 1.48 | 2.30 | 1.78 | 2.37 | 2.20 | 2.34 | 3.28 | 2.44 | 3.45 |
Last Updated: August 20, 2025, 10:45 am
Below is a detailed analysis of the quarterly data for Fortis Healthcare Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 2,167.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,007.00 Cr. (Mar 2025) to 2,167.00 Cr., marking an increase of 160.00 Cr..
- For Expenses, as of Jun 2025, the value is 1,676.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,572.00 Cr. (Mar 2025) to 1,676.00 Cr., marking an increase of 104.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 491.00 Cr.. The value appears strong and on an upward trend. It has increased from 435.00 Cr. (Mar 2025) to 491.00 Cr., marking an increase of 56.00 Cr..
- For OPM %, as of Jun 2025, the value is 23.00%. The value appears strong and on an upward trend. It has increased from 22.00% (Mar 2025) to 23.00%, marking an increase of 1.00%.
- For Other Income, as of Jun 2025, the value is 31.00 Cr.. The value appears strong and on an upward trend. It has increased from -29.00 Cr. (Mar 2025) to 31.00 Cr., marking an increase of 60.00 Cr..
- For Interest, as of Jun 2025, the value is 70.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 68.00 Cr. (Mar 2025) to 70.00 Cr., marking an increase of 2.00 Cr..
- For Depreciation, as of Jun 2025, the value is 101.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 102.00 Cr. (Mar 2025) to 101.00 Cr., marking a decrease of 1.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 351.00 Cr.. The value appears strong and on an upward trend. It has increased from 237.00 Cr. (Mar 2025) to 351.00 Cr., marking an increase of 114.00 Cr..
- For Tax %, as of Jun 2025, the value is 24.00%. The value appears to be increasing, which may not be favorable. It has increased from 21.00% (Mar 2025) to 24.00%, marking an increase of 3.00%.
- For Net Profit, as of Jun 2025, the value is 267.00 Cr.. The value appears strong and on an upward trend. It has increased from 188.00 Cr. (Mar 2025) to 267.00 Cr., marking an increase of 79.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 3.45. The value appears strong and on an upward trend. It has increased from 2.44 (Mar 2025) to 3.45, marking an increase of 1.01.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:22 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,492 | 3,966 | 4,199 | 4,574 | 4,561 | 4,469 | 4,632 | 4,030 | 5,718 | 6,298 | 6,893 | 7,783 | 8,434 |
| Expenses | 3,430 | 3,857 | 4,106 | 4,220 | 4,287 | 4,238 | 4,022 | 3,626 | 4,649 | 5,196 | 5,625 | 6,195 | 6,576 |
| Operating Profit | 62 | 109 | 92 | 354 | 274 | 231 | 610 | 404 | 1,069 | 1,101 | 1,268 | 1,588 | 1,858 |
| OPM % | 2% | 3% | 2% | 8% | 6% | 5% | 13% | 10% | 19% | 17% | 18% | 20% | 22% |
| Other Income | 152 | 92 | 299 | 649 | -689 | 228 | 126 | 95 | 367 | 157 | 64 | -11 | 98 |
| Interest | 250 | 152 | 133 | 229 | 258 | 337 | 205 | 166 | 147 | 129 | 131 | 184 | 257 |
| Depreciation | 183 | 235 | 225 | 222 | 239 | 233 | 292 | 291 | 301 | 316 | 342 | 386 | 407 |
| Profit before tax | -219 | -185 | 34 | 552 | -912 | -110 | 239 | 43 | 988 | 814 | 858 | 1,007 | 1,292 |
| Tax % | 5% | 2% | -24% | 13% | 2% | 103% | 62% | 230% | 20% | 22% | 25% | 20% | |
| Net Profit | -218 | -130 | 42 | 479 | -934 | -224 | 91 | -56 | 790 | 633 | 645 | 809 | 1,038 |
| EPS in Rs | -4.73 | -3.10 | 0.40 | 8.14 | -19.46 | -3.96 | 0.77 | -1.45 | 7.35 | 7.80 | 7.93 | 10.26 | 13.43 |
| Dividend Payout % | -0% | -1% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 13% | 13% | 10% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 40.37% | 132.31% | 1040.48% | -294.99% | 76.02% | 140.62% | -161.54% | 1510.71% | -19.87% | 1.90% | 25.43% |
| Change in YoY Net Profit Growth (%) | 0.00% | 91.94% | 908.17% | -1335.47% | 371.01% | 64.61% | -302.16% | 1672.25% | -1530.59% | 21.77% | 23.53% |
Fortis Healthcare Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 11% |
| 3 Years: | 11% |
| TTM: | 14% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 23% |
| 5 Years: | 70% |
| 3 Years: | 31% |
| TTM: | 43% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 20% |
| 5 Years: | 48% |
| 3 Years: | 49% |
| 1 Year: | 69% |
| Return on Equity | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 6% |
| 3 Years: | 9% |
| Last Year: | 10% |
Last Updated: September 5, 2025, 4:15 am
Balance Sheet
Last Updated: December 4, 2025, 1:15 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 463 | 463 | 463 | 518 | 519 | 755 | 755 | 755 | 755 | 755 | 755 | 755 | 755 |
| Reserves | 3,820 | 3,585 | 3,998 | 4,626 | 3,543 | 5,846 | 5,906 | 5,365 | 5,423 | 6,487 | 6,908 | 8,162 | 8,674 |
| Borrowings | 2,550 | 1,784 | 1,513 | 2,217 | 1,962 | 2,010 | 1,594 | 1,531 | 1,255 | 926 | 1,155 | 2,475 | 3,195 |
| Other Liabilities | 1,018 | 1,760 | 1,257 | 2,227 | 2,455 | 2,875 | 2,781 | 3,216 | 4,082 | 3,921 | 4,153 | 1,985 | 2,389 |
| Total Liabilities | 7,851 | 7,592 | 7,232 | 9,588 | 8,479 | 11,486 | 11,036 | 10,866 | 11,516 | 12,089 | 12,971 | 13,377 | 15,013 |
| Fixed Assets | 4,147 | 4,218 | 3,642 | 5,419 | 4,992 | 8,477 | 8,802 | 8,799 | 9,416 | 9,426 | 9,874 | 10,424 | 11,703 |
| CWIP | 147 | 228 | 226 | 268 | 226 | 450 | 204 | 165 | 193 | 228 | 542 | 407 | 306 |
| Investments | 1,817 | 1,464 | 1,452 | 1,878 | 1,732 | 270 | 175 | 186 | 104 | 210 | 230 | 169 | 220 |
| Other Assets | 1,739 | 1,682 | 1,913 | 2,023 | 1,529 | 2,290 | 1,856 | 1,716 | 1,803 | 2,225 | 2,326 | 2,378 | 2,784 |
| Total Assets | 7,851 | 7,592 | 7,232 | 9,588 | 8,479 | 11,486 | 11,036 | 10,866 | 11,516 | 12,089 | 12,971 | 13,377 | 15,013 |
Below is a detailed analysis of the balance sheet data for Fortis Healthcare Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 755.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 755.00 Cr..
- For Reserves, as of Sep 2025, the value is 8,674.00 Cr.. The value appears strong and on an upward trend. It has increased from 8,162.00 Cr. (Mar 2025) to 8,674.00 Cr., marking an increase of 512.00 Cr..
- For Borrowings, as of Sep 2025, the value is 3,195.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 2,475.00 Cr. (Mar 2025) to 3,195.00 Cr., marking an increase of 720.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 2,389.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,985.00 Cr. (Mar 2025) to 2,389.00 Cr., marking an increase of 404.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 15,013.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 13,377.00 Cr. (Mar 2025) to 15,013.00 Cr., marking an increase of 1,636.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 11,703.00 Cr.. The value appears strong and on an upward trend. It has increased from 10,424.00 Cr. (Mar 2025) to 11,703.00 Cr., marking an increase of 1,279.00 Cr..
- For CWIP, as of Sep 2025, the value is 306.00 Cr.. The value appears to be declining and may need further review. It has decreased from 407.00 Cr. (Mar 2025) to 306.00 Cr., marking a decrease of 101.00 Cr..
- For Investments, as of Sep 2025, the value is 220.00 Cr.. The value appears strong and on an upward trend. It has increased from 169.00 Cr. (Mar 2025) to 220.00 Cr., marking an increase of 51.00 Cr..
- For Other Assets, as of Sep 2025, the value is 2,784.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,378.00 Cr. (Mar 2025) to 2,784.00 Cr., marking an increase of 406.00 Cr..
- For Total Assets, as of Sep 2025, the value is 15,013.00 Cr.. The value appears strong and on an upward trend. It has increased from 13,377.00 Cr. (Mar 2025) to 15,013.00 Cr., marking an increase of 1,636.00 Cr..
Notably, the Reserves (8,674.00 Cr.) exceed the Borrowings (3,195.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 60.00 | 108.00 | 91.00 | 352.00 | 273.00 | 229.00 | 609.00 | 403.00 | 0.00 | -925.00 | 0.00 | -1.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 46 | 38 | 39 | 38 | 38 | 44 | 36 | 41 | 33 | 34 | 33 | 37 |
| Inventory Days | 26 | 25 | 23 | 23 | 24 | 22 | 30 | 29 | 33 | 31 | 24 | 23 |
| Days Payable | 200 | 207 | 218 | 215 | 279 | 296 | 226 | 205 | 178 | 179 | 164 | 161 |
| Cash Conversion Cycle | -128 | -144 | -156 | -155 | -217 | -230 | -161 | -135 | -112 | -115 | -107 | -101 |
| Working Capital Days | -19 | -71 | -69 | -87 | -113 | -234 | -150 | -56 | -35 | -22 | -124 | -30 |
| ROCE % | 0% | -0% | 3% | 11% | 3% | 6% | 4% | 2% | 10% | 10% | 10% | 12% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| HDFC Mid Cap Fund | 27,834,044 | 2.78 | 2558.23 | N/A | N/A | N/A |
| Kotak Midcap Fund | 24,724,343 | 3.76 | 2272.41 | N/A | N/A | N/A |
| Nippon India Growth Mid Cap Fund | 13,542,021 | 2.96 | 1244.65 | N/A | N/A | N/A |
| Axis Midcap Fund | 12,427,065 | 3.55 | 1142.17 | 12,674,257 | 2025-12-15 02:41:06 | -1.95% |
| HDFC Small Cap Fund | 9,440,132 | 2.28 | 867.64 | 9,973,132 | 2025-12-15 02:41:06 | -5.34% |
| DSP Mid Cap Fund | 5,152,245 | 2.39 | 473.54 | 5,166,727 | 2025-12-15 02:41:06 | -0.28% |
| Aditya Birla Sun Life ELSS Tax Saver Fund | 4,912,331 | 2.88 | 451.49 | 8,360,144 | 2025-12-07 02:17:25 | -41.24% |
| HDFC Large and Mid Cap Fund | 4,733,349 | 1.51 | 435.04 | N/A | N/A | N/A |
| Kotak Large & Midcap Fund | 4,200,000 | 1.29 | 386.02 | N/A | N/A | N/A |
| Sundaram Mid Cap Fund | 3,592,166 | 2.47 | 330.16 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 10.26 | 7.93 | 7.80 | 7.35 | -1.45 |
| Diluted EPS (Rs.) | 10.26 | 7.93 | 7.80 | 7.35 | -1.45 |
| Cash EPS (Rs.) | 15.68 | 12.96 | 12.28 | 14.13 | 2.48 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 118.11 | 113.33 | 107.30 | 92.83 | 88.98 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 118.11 | 113.33 | 107.30 | 92.83 | 88.98 |
| Revenue From Operations / Share (Rs.) | 103.09 | 91.30 | 83.42 | 75.73 | 53.38 |
| PBDIT / Share (Rs.) | 21.92 | 17.30 | 15.40 | 14.52 | 5.97 |
| PBIT / Share (Rs.) | 16.81 | 12.76 | 11.22 | 10.54 | 2.12 |
| PBT / Share (Rs.) | 13.19 | 11.24 | 10.49 | 12.76 | -0.05 |
| Net Profit / Share (Rs.) | 10.57 | 8.42 | 8.10 | 10.14 | -1.37 |
| NP After MI And SOA / Share (Rs.) | 10.26 | 7.93 | 7.80 | 7.35 | -1.45 |
| PBDIT Margin (%) | 21.26 | 18.94 | 18.46 | 19.17 | 11.19 |
| PBIT Margin (%) | 16.30 | 13.97 | 13.45 | 13.91 | 3.98 |
| PBT Margin (%) | 12.79 | 12.30 | 12.57 | 16.85 | -0.10 |
| Net Profit Margin (%) | 10.25 | 9.22 | 9.70 | 13.39 | -2.57 |
| NP After MI And SOA Margin (%) | 9.94 | 8.68 | 9.34 | 9.70 | -2.72 |
| Return on Networth / Equity (%) | 8.68 | 7.81 | 8.12 | 8.98 | -1.79 |
| Return on Capital Employeed (%) | 10.50 | 9.52 | 7.69 | 7.49 | 1.61 |
| Return On Assets (%) | 5.65 | 4.50 | 4.73 | 4.67 | -0.98 |
| Long Term Debt / Equity (X) | 0.23 | 0.09 | 0.07 | 0.12 | 0.15 |
| Total Debt / Equity (X) | 0.24 | 0.11 | 0.09 | 0.15 | 0.18 |
| Asset Turnover Ratio (%) | 0.57 | 0.53 | 0.09 | 0.07 | 0.05 |
| Current Ratio (X) | 0.91 | 0.44 | 0.98 | 0.89 | 0.84 |
| Quick Ratio (X) | 0.84 | 0.41 | 0.90 | 0.79 | 0.77 |
| Inventory Turnover Ratio (X) | 69.89 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend Payout Ratio (NP) (%) | 9.99 | 12.60 | 0.00 | 0.00 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 6.67 | 8.01 | 0.00 | 0.00 | 0.00 |
| Earning Retention Ratio (%) | 90.01 | 87.40 | 0.00 | 0.00 | 0.00 |
| Cash Earning Retention Ratio (%) | 93.33 | 91.99 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 8.97 | 9.97 | 9.01 | 7.47 | 2.72 |
| Interest Coverage Ratio (Post Tax) (X) | 5.81 | 5.73 | 5.16 | 4.07 | 0.36 |
| Enterprise Value (Cr.) | 54674.02 | 32853.83 | 20823.69 | 23306.97 | 16352.45 |
| EV / Net Operating Revenue (X) | 7.03 | 4.77 | 3.31 | 4.08 | 4.06 |
| EV / EBITDA (X) | 33.04 | 25.16 | 17.90 | 21.26 | 36.26 |
| MarketCap / Net Operating Revenue (X) | 6.78 | 4.60 | 3.12 | 3.83 | 3.73 |
| Retention Ratios (%) | 90.00 | 87.39 | 0.00 | 0.00 | 0.00 |
| Price / BV (X) | 5.91 | 4.14 | 2.71 | 3.55 | 2.45 |
| Price / Net Operating Revenue (X) | 6.78 | 4.60 | 3.12 | 3.83 | 3.73 |
| EarningsYield | 0.01 | 0.01 | 0.02 | 0.02 | -0.01 |
After reviewing the key financial ratios for Fortis Healthcare Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 10.26. This value is within the healthy range. It has increased from 7.93 (Mar 24) to 10.26, marking an increase of 2.33.
- For Diluted EPS (Rs.), as of Mar 25, the value is 10.26. This value is within the healthy range. It has increased from 7.93 (Mar 24) to 10.26, marking an increase of 2.33.
- For Cash EPS (Rs.), as of Mar 25, the value is 15.68. This value is within the healthy range. It has increased from 12.96 (Mar 24) to 15.68, marking an increase of 2.72.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 118.11. It has increased from 113.33 (Mar 24) to 118.11, marking an increase of 4.78.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 118.11. It has increased from 113.33 (Mar 24) to 118.11, marking an increase of 4.78.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 103.09. It has increased from 91.30 (Mar 24) to 103.09, marking an increase of 11.79.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 21.92. This value is within the healthy range. It has increased from 17.30 (Mar 24) to 21.92, marking an increase of 4.62.
- For PBIT / Share (Rs.), as of Mar 25, the value is 16.81. This value is within the healthy range. It has increased from 12.76 (Mar 24) to 16.81, marking an increase of 4.05.
- For PBT / Share (Rs.), as of Mar 25, the value is 13.19. This value is within the healthy range. It has increased from 11.24 (Mar 24) to 13.19, marking an increase of 1.95.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 10.57. This value is within the healthy range. It has increased from 8.42 (Mar 24) to 10.57, marking an increase of 2.15.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 10.26. This value is within the healthy range. It has increased from 7.93 (Mar 24) to 10.26, marking an increase of 2.33.
- For PBDIT Margin (%), as of Mar 25, the value is 21.26. This value is within the healthy range. It has increased from 18.94 (Mar 24) to 21.26, marking an increase of 2.32.
- For PBIT Margin (%), as of Mar 25, the value is 16.30. This value is within the healthy range. It has increased from 13.97 (Mar 24) to 16.30, marking an increase of 2.33.
- For PBT Margin (%), as of Mar 25, the value is 12.79. This value is within the healthy range. It has increased from 12.30 (Mar 24) to 12.79, marking an increase of 0.49.
- For Net Profit Margin (%), as of Mar 25, the value is 10.25. This value exceeds the healthy maximum of 10. It has increased from 9.22 (Mar 24) to 10.25, marking an increase of 1.03.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 9.94. This value is within the healthy range. It has increased from 8.68 (Mar 24) to 9.94, marking an increase of 1.26.
- For Return on Networth / Equity (%), as of Mar 25, the value is 8.68. This value is below the healthy minimum of 15. It has increased from 7.81 (Mar 24) to 8.68, marking an increase of 0.87.
- For Return on Capital Employeed (%), as of Mar 25, the value is 10.50. This value is within the healthy range. It has increased from 9.52 (Mar 24) to 10.50, marking an increase of 0.98.
- For Return On Assets (%), as of Mar 25, the value is 5.65. This value is within the healthy range. It has increased from 4.50 (Mar 24) to 5.65, marking an increase of 1.15.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.23. This value is within the healthy range. It has increased from 0.09 (Mar 24) to 0.23, marking an increase of 0.14.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.24. This value is within the healthy range. It has increased from 0.11 (Mar 24) to 0.24, marking an increase of 0.13.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.57. It has increased from 0.53 (Mar 24) to 0.57, marking an increase of 0.04.
- For Current Ratio (X), as of Mar 25, the value is 0.91. This value is below the healthy minimum of 1.5. It has increased from 0.44 (Mar 24) to 0.91, marking an increase of 0.47.
- For Quick Ratio (X), as of Mar 25, the value is 0.84. This value is below the healthy minimum of 1. It has increased from 0.41 (Mar 24) to 0.84, marking an increase of 0.43.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 69.89. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 24) to 69.89, marking an increase of 69.89.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 9.99. This value is below the healthy minimum of 20. It has decreased from 12.60 (Mar 24) to 9.99, marking a decrease of 2.61.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 6.67. This value is below the healthy minimum of 20. It has decreased from 8.01 (Mar 24) to 6.67, marking a decrease of 1.34.
- For Earning Retention Ratio (%), as of Mar 25, the value is 90.01. This value exceeds the healthy maximum of 70. It has increased from 87.40 (Mar 24) to 90.01, marking an increase of 2.61.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 93.33. This value exceeds the healthy maximum of 70. It has increased from 91.99 (Mar 24) to 93.33, marking an increase of 1.34.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 8.97. This value is within the healthy range. It has decreased from 9.97 (Mar 24) to 8.97, marking a decrease of 1.00.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 5.81. This value is within the healthy range. It has increased from 5.73 (Mar 24) to 5.81, marking an increase of 0.08.
- For Enterprise Value (Cr.), as of Mar 25, the value is 54,674.02. It has increased from 32,853.83 (Mar 24) to 54,674.02, marking an increase of 21,820.19.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 7.03. This value exceeds the healthy maximum of 3. It has increased from 4.77 (Mar 24) to 7.03, marking an increase of 2.26.
- For EV / EBITDA (X), as of Mar 25, the value is 33.04. This value exceeds the healthy maximum of 15. It has increased from 25.16 (Mar 24) to 33.04, marking an increase of 7.88.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 6.78. This value exceeds the healthy maximum of 3. It has increased from 4.60 (Mar 24) to 6.78, marking an increase of 2.18.
- For Retention Ratios (%), as of Mar 25, the value is 90.00. This value exceeds the healthy maximum of 70. It has increased from 87.39 (Mar 24) to 90.00, marking an increase of 2.61.
- For Price / BV (X), as of Mar 25, the value is 5.91. This value exceeds the healthy maximum of 3. It has increased from 4.14 (Mar 24) to 5.91, marking an increase of 1.77.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 6.78. This value exceeds the healthy maximum of 3. It has increased from 4.60 (Mar 24) to 6.78, marking an increase of 2.18.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Fortis Healthcare Ltd:
- Net Profit Margin: 10.25%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 10.5% (Industry Average ROCE: 15.48%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 8.68% (Industry Average ROE: 14.81%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 5.81
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.84
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 67 (Industry average Stock P/E: 92.44)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.24
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 10.25%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Hospitals & Medical Services | Fortis Hospital, Sector 62, Phase - VIII, Mohali Punjab 160062 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Ashutosh Raghuvanshi | Managing Director & CEO |
| Ms. Suvalaxmi Chakraborty | Independent Director |
| Mr. Indrajit Banerjee | Independent Director |
| Ms. Shailaja Chandra | Independent Director |
| Mr. Tomo Nagahiro | Non Executive Director |
| Mr. Dilip Kadambi | Non Executive Director |
| Mr. Lim Tsin Lin | Non Executive Director |
| Mr. Mehmet Ali Aydinlar | Non Executive Director |
| Dr. Prem Kumar Nair | Non Executive Director |
| Mr. Ashok Pandit | Non Executive Director |
| Mr. Leo Puri | Chairman & Ind.Director |
FAQ
What is the intrinsic value of Fortis Healthcare Ltd?
Fortis Healthcare Ltd's intrinsic value (as of 29 December 2025) is 677.44 which is 24.14% lower the current market price of 893.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 67,448 Cr. market cap, FY2025-2026 high/low of 1,105/521, reserves of ₹8,674 Cr, and liabilities of 15,013 Cr.
What is the Market Cap of Fortis Healthcare Ltd?
The Market Cap of Fortis Healthcare Ltd is 67,448 Cr..
What is the current Stock Price of Fortis Healthcare Ltd as on 29 December 2025?
The current stock price of Fortis Healthcare Ltd as on 29 December 2025 is 893.
What is the High / Low of Fortis Healthcare Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Fortis Healthcare Ltd stocks is 1,105/521.
What is the Stock P/E of Fortis Healthcare Ltd?
The Stock P/E of Fortis Healthcare Ltd is 67.0.
What is the Book Value of Fortis Healthcare Ltd?
The Book Value of Fortis Healthcare Ltd is 125.
What is the Dividend Yield of Fortis Healthcare Ltd?
The Dividend Yield of Fortis Healthcare Ltd is 0.11 %.
What is the ROCE of Fortis Healthcare Ltd?
The ROCE of Fortis Healthcare Ltd is 12.0 %.
What is the ROE of Fortis Healthcare Ltd?
The ROE of Fortis Healthcare Ltd is 10.1 %.
What is the Face Value of Fortis Healthcare Ltd?
The Face Value of Fortis Healthcare Ltd is 10.0.